

FORM PTO-1449 QIP E SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT APR 25 2006 (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 25, 2003	GROUP 1617

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,670,349	12-30-03	Nyce			01-20-00
	6,372,732	04-16-02	Lardy et al.			05-27-99
	6,207,703	03-27-01	Ponikau			10-22-98
	6,172,088	01-09-01	Simpkins et al.			11-24-98
	6,046,185	04-02-00	Burgoyne et al.			07-10-97
	6,087,351	07-11-00	Nyce			05-22-97
	5,837,713	11-17-98	Gleich			
	5,660,835	08-26-97	Nyce			
	5,641,768	06-24-97	Loria			
	5,506,221	04-09-96	Anderson et al.			
	5,405,842	04-11-95	Silverman			
	5,116,829	05-26-92	Hori et al.			
	4,897,390	01-30-90	Ruhe			
	4,628,052	12-09-86	Peat			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.)
	Auci D, et al., Anti-inflammatory and immune regulatory properties of 5-androsten-3 β ,17 β -diol (HE2100) and synthetic analogue HE3204 Implications for treatment of autoimmune diseases, <i>Ann. N.Y. Acad. Sci.</i> , 1051:730 – 742 2005
	Offner H, A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse, <i>Clin. Immun.</i> , 110:181 – 190 2004

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	